2022
Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US
Lang R, Humes E, Coburn SB, Horberg MA, Fathi LF, Watson E, Jefferson CR, Park LS, Gordon KS, Akgün KM, Justice AC, Napravnik S, Edwards JK, Browne LE, Agil DM, Silverberg MJ, Skarbinski J, Leyden WA, Stewart C, Hogan BC, Gebo KA, Marconi VC, Williams CF, Althoff KN. Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US. JAMA Network Open 2022, 5: e2236397. PMID: 36227594, PMCID: PMC9561947, DOI: 10.1001/jamanetworkopen.2022.36397.Peer-Reviewed Original ResearchConceptsBreakthrough COVID-19Breakthrough infectionsHIV statusCohort studySevere illnessMAIN OUTCOMEBreakthrough SARS-CoV-2 infectionCOVID-19 vaccine typesLow CD4 cell countsSARS-CoV-2 infectionCOVID-19Severe immune suppressionCD4 cell countProportion of patientsCells/μLPrevious COVID-19Additional vaccine dosesProportional hazards modelDiscrete-time proportional hazards modelsRisk reduction recommendationsVaccine guidelinesCD4 cellsCumulative incidenceHazard ratioClinical factors
2019
Association of Prescribed Opioids With Increased Risk of Community-Acquired Pneumonia Among Patients With and Without HIV
Edelman EJ, Gordon KS, Crothers K, Akgün K, Bryant KJ, Becker WC, Gaither JR, Gibert CL, Gordon AJ, Marshall BDL, Rodriguez-Barradas MC, Samet JH, Justice AC, Tate JP, Fiellin DA. Association of Prescribed Opioids With Increased Risk of Community-Acquired Pneumonia Among Patients With and Without HIV. JAMA Internal Medicine 2019, 179: 297-304. PMID: 30615036, PMCID: PMC6439696, DOI: 10.1001/jamainternmed.2018.6101.Peer-Reviewed Original ResearchConceptsVeterans Aging Cohort StudyCommunity-acquired pneumoniaImmunosuppressive propertiesPrescribed opioidsCaP riskHIV statusMedian morphine equivalent daily doseVeterans Health Administration medical centersMorphine equivalent daily doseEquivalent daily doseAging Cohort StudyCase-control studyImmune-related outcomesRace/ethnicityIndex dateOpioid exposureCohort studyDaily doseOpioid propertiesStratified analysisMedical CenterMAIN OUTCOMEOpioidsMedicaid dataHIV